Trinity Biotech shares surge 88.33% premarket after $9M HIV test order and Q3 revenue jump to $14.3M with positive Adjusted EBITDA.

Trinity Biotech surged 88.33% in premarket trading following multiple positive developments. The company secured a 9 million-unit order for its WHO-prequalified TrinScreen HIV rapid test, expected to fulfill in late 2025 and early 2026, signaling renewed demand in global HIV diagnostics. Concurrently, Q3 2025 revenue rose 32% to $14.3M, with Adjusted EBITDA turning positive at $0.5M, reflecting operational improvements under its transformation plan. Additionally, Trinity announced $5 million in new term-loan funding and $60 million in elective equity settlement capacity with Perceptive Advisors, enhancing liquidity and reducing debt costs. These milestones—securing a major order, improved profitability, and strengthened capital structure—collectively drove investor optimism, aligning with the stock’s sharp premarket rise.